Sex Hormone Receptor Repertoire in Breast Cancer

Gerald M. Higa¹² and Ryan G. Fell³

¹ Schools of Pharmacy and Medicine, West Virginia University, Morgantown, WV 26506, USA
² Robert C. Byrd Health Sciences Center, West Virginia University, One Medical Center Drive, P.O. Box 9520, Morgantown, WV 26506, USA
³ School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA

Correspondence should be addressed to Gerald M. Higa; ghiga@hsc.wvu.edu

Received 17 July 2013; Revised 7 September 2013; Accepted 10 September 2013

Academic Editor: Bent Ejlertsen

Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ERα is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of other receptors in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ERβ and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ERβ-mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer.

1. Introduction

Epidemiological, biological, and clinical data strongly implicate the role of sex hormones, primarily estrogens, in breast cancer; yet, their mere presence does not contribute to the malignant process. Inherent in this technically accurate paradox is that while the former supports the well-established link between estrogens, and possibly androgens, in this endocrine-related cancer, the latter infers that generation of the malignant phenotype requires other cellular components. Perhaps the most important “other” element is the hormone receptor. While the ligand/receptor construct is conceptually very simple, the molecular mechanisms by which sex hormones regulate a number of dynamic yet delicate processes in their target tissues are exceedingly more complex.

The impetus for undertaking this endeavor was to merge our increased, though by no means complete, understanding of the estrogen and androgen receptors in breast cancer. As such, numerous published papers, some old but of enduring scientific value, were evaluated to support the conclusion that the nuclear steroid receptors are the essential link between hormone and disease. And to further enhance reader appreciation of this complex structure, the biology of the receptor is briefly reviewed in order to provide additional insight into the proposed mechanisms which promote tumor growth as well as facilitate tumor resistance. Here, the reader can learn a little about the treatment of hormone-dependent breast cancer, more about how cell biology might improve our understanding of this disease, and perhaps better appreciate the role receptors have in a disease that may be more appropriately referred to as sex hormone receptor-dependent breast cancer.

2. Evolving Principles

Although an association between estrogens and breast cancer was recognized over a century ago [1], a valid explanation for how estrogens exert their tissue-specific actions was not forthcoming for another 60 years. Rather than their speculated role in enzyme-mediated metabolic processes,
Table 1: Receptor-mediated effects and features in breast cancer.

|                | ERα       | ERβ       | ERα/ERβ heterodimer | AR            |
|----------------|-----------|-----------|---------------------|---------------|
| **Proliferation** | Stimulates (in the presence of E2 and coactivators) | Suppresses but may depend on variant (only ERβ binds E2 with high affinity) | Data support suppression but may depend on ERβ variant and density of each receptor subtype | Stimulates or suppresses (may depend on concurrent signaling pathways activated) |
| **Apoptosis**   | Suppresses (in the presence of E2 and coactivators) | Promotes (but may depend on variant) | Data support promotion but may depend on ERβ variant and density of each receptor subtype | Stimulates or suppresses (may depend on concurrent signaling pathways or variant) |

**PR gene**

| Prognostic factor | Activates | Represses activation | Represses activation | — |
|-------------------|-----------|----------------------|----------------------|----|
| ERE binding       | Yes       | Only ERβ, βins, and ERβ2 bind ERE | Uncertain but possible | Androgen response element (ARE) |
| Dimerization with ERα and ERβ1 | Yes | Yes for wild type and βins; ERβ2 binds ERα only | — | No |
| **Receptor variants** | Best characterized is hER-alpha36 | At least 5 (ERβ1 (wild type), delta5, 18 a.a insert (βins), ERβcx (ERβ2), and β5) | — | At least 7 splice variants have been identified (AR-V1, AR-V2, AR-V3, AR-V4, AR-V5, AR-V6, and AR-V7) but many more likely to exist |
| **AF-2** | Independent | Dependent | — | — |

Interaction with other signaling pathways

|                | Yes | Yes | Yes | Yes |

A protein receptor was identified as the critical component to mediate the broad repertoire of hormonal actions including estrogen-stimulated growth of breast cancer cells [2]. What later became the target for new strategies to treat breast cancer, the estrogen receptor (ER) was also on the verge of being associated with the disease in two defining ways. First, as a predictive factor, in that the ER emerged as the single most useful determinant to guide application of (and likely, response to) endocrine therapies [3]; and second, as a prognostic factor, in that independent of treatment, tumor cell expression of this hormone receptor was associated with improved disease outcomes [4]. More recently, the ER has been linked to two molecular subtypes of breast cancer identified as luminal A and luminal B [5]. Further testing of ER-positive (ER+) tumors by analyzing expression of a panel of genes resulted in groundbreaking information for managing women with early-stage hormone-dependent breast cancer [6]. Translated to a “recurrence score,” the multigene test had, like ER, both prognostic value (quantified the risk of disease recurrence) and predictive value (estimated the benefit of adding chemotherapy).

These noteworthy attributes may have, in large part, preempted the potential importance of the second ER, which was discovered less than two decades ago [7]. Because of this new finding, what was traditionally referred to as ER, subsequently became known as ERα. Even though accumulating data suggest the more recently identified estrogen receptor (i.e., ERβ) may have biological and clinical relevance, the majority of the published reports support the preeminence of ERα, even in tumor cells that coexpress both ER subtypes. While this conclusion is consistent with reports that breast cancer survival was not influenced by ERβ expression in patients with ERα+ or ERα-negative (ER−) tumors [8, 9], other investigators found a direct correlation between ERβ-positivity and overall survival [10]. A confounding factor that could provide a partial explanation for this discrepancy is the variable expression of one or more ERβ variants in breast cancer (Table 1). Because of the potential clinical relevance of ERβ, a comprehensive discussion of this issue is provided in the ERβ section which follows later.

Interestingly, expression of the androgen receptor (AR) in primary breast tumors and metastatic lesions predated the discovery of ERβ [11]. However, like ERβ, the clinical significance of its presence in tumor cells remains uncertain. Nevertheless, a number of studies suggest that the AR may have prognostic value, independent of ERα expression. For example, even though AR is frequently present in ERα+ breast cancers, AR has also been found in a significant percentage of ERβ+ tumors [12, 13]. These observations may be clinically relevant for the following reason. Because tumor cell expression of ERα correlates with tumor size, histologic grade, and axillary node metastasis, it may be difficult to argue that the relatively good prognosis of ERα+ breast cancers should be attributed, in part, to coexpressed AR. However, the finding that expression of AR in ERβ+ tumors was associated with increased age, postmenopausal status, lower tumor grade, smaller tumor size, and significantly improved disease-free survival suggests otherwise [13]. Moreover, the absence of AR appeared to be associated with higher levels of Ki-67, a cell proliferation marker. Collectively, these
mediated through the DBD is perhaps the most important described. There is convincing evidence that dimerization, receptor dimerization, of which three forms have been component of signaling mediated through AR depends on localized to the latter domain is AF-2.

3. Receptor Biology

The sex hormone receptors, which belong to the steroid/thyroid superfamily of nuclear receptors, mediate the genomic action of estrogens by acting as ligand-dependent transcription factors [15]. All members of the hormone-inducible nuclear receptors share three distinct but not autonomously functioning domains (Figure 1). First, although the NH2-terminal domain (NTD) contains activating factor (AF)-1, which serves as the focus for transcription factor interaction and target-gene activation, the activities of the AF-1 domain differ substantially between the two ERs [16]. The nature of this disparity is discussed in the ERα/ERβ heterodimer section. Next, the DNA-binding domain (DBD) contains two highly conserved zinc-finger regions that are essential for high-affinity binding to estrogen response elements (EREs) in target genes and comodulating receptor dimerization with the ligand-binding domain (LBD). And third, the C-terminus domain mediates ligand-binding, receptor dimerization, and nuclear translocation. Localized to the latter domain is AF-2.

Although having similar functional domains, a critical component of signaling mediated through AR depends on receptor dimerization, of which three forms have been described. There is convincing evidence that dimerization mediated through the DBD is perhaps the most important [17, 18]. Of note, the DBD of both AR and ER is enriched with two cysteine zinc finger motifs and a C-terminal extension (CTE) [19]. However, in contrast to the ERs, the first 12 amino acids of the CTE are essential for AR-specific DNA binding [20, 21]. A second form of AR dimerization occurs through an interaction between two discrete sites in the N-terminal and C-terminal (N/C) [22]. Induced only by AR agonists such as 5α-dihydrotestosterone and testosterone, the N/C interaction stabilizes the receptor by slowing the rate of steroid dissociation and receptor degradation [23, 24]. Furthermore, the N/C interaction appears to be a critical regulator of chromatin binding and transcription [25]. Lastly, compared to LBD-mediated dimerization (the third form) of ER, much less is known about the specific sites involved with AR [26]. Collectively, our current knowledge strongly suggests that dimerization processed through the DBD is an absolute requirement for AR-mediated signaling.

Even though our understanding of the receptor multiplex continues to evolve, construction of exquisite three-dimensional models has made it possible to better appreciate and even visualize the submicroscopic precision of the hormone/receptor interaction. The primal event of ligand binding at the C-terminal end induces conformational changes in the receptor and activates intrinsic AF-2. Crystallographic studies of the LBD revealed that the AF-2 interaction platform is composed of five helices, the most important of which appears to be positioning of helix 12. When estradiol binds ERα, helix 12 is oriented over the ligand-binding pocket creating an “agonist” interface for recruitment of coactivators (Figure 2) [27]. On the other hand, the tamoxifen/ERα complex results in displacement of helix 12 from its agonist position and, instead, occupies the lipophilic pocket formed by helices 3, 5/6, and 11. In this context, helix 12 disrupts the coactivator interactive surface. Hence, ligand-induced reorientation of helix 12 is not
only an important feature which discriminates ER agonists from antagonists but also essential for receptor-mediated transcriptional activity. Similarly, androgen-bound receptor promotes conformational rearrangements in the LBD resulting in formation of AF-2 [28]. Interesting however, unlike ER AF-2 which is the principal mediator of transcriptional activity through coregulator binding in the LBD, the AR AF-2 domain preferentially interacts with amino acid motifs found in the N-terminal domain. As such, recruited and bound coregulators make the NTD of AR the primary site of transcriptional activity [29, 30].

In contrast, the molecular basis of how the hormone-bound receptor interacts with the nuclear transcriptional elements makes the ligand binding process look relatively simple as recruitment of additional coregulators and involvement of epigenetic proteins has been shown to be essential in order to fine tune hormonal activity [31]. In addition, transcription can be activated or repressed depending on the recruitment, or balance, of the comodulatory components. Examples of both types of transcriptional activity are illustrated using estrogen actions on the skeleton as osteocytes contain ERα (Figure 3). Whereas many of the genes that affect bone metabolism have been identified, the manner in which transcription takes place depends on surreptitiously precise interactions with a number of coactivator complexes.

Although negative feedback is a unique biological characteristic of the endocrine system, molecular evidence suggests that part of the mechanism for self-attenuation or inhibition of receptor-mediated signaling depends on the presence of corepressors (Figure 3). As indicated previously, estrogen-induced rotation of helix 12 within the AF-2 domain facilitates coactivator binding. However, in the presence of the antiestrogens tamoxifen and raloxifene, an alternative conformation in the LBD of ER in which helix 12 blocks the coactivator recognition site results which favors corepressor binding [27].

In essence, the ultimate effect of hormones on target tissue depends on the balance of coactivators and corepressors recruited to the receptor. This concept is relevant in breast cancer because receptor-mediated effects appear to result from both upregulation of specific genes that contribute to tumor growth and survival as well as downregulation of genes that possess repressive effects on proliferation and apoptosis. Indeed, ERα-targeted gene expression can be downregulated in the presence of receptor corepressors which consequently blunt the effect of estrogens on tumor cell proliferation [32]. While the impact of corepressors may be restricted to receptor-expressing (i.e., ERα+) and hormone-dependent tumor cells, the development of hormone-independent breast cancers could also be partly linked to diminished corepressor activity. This conclusion is supported by the following: (1) it has been shown that corepressors bound to unliganded ERα are dislodged by estradiol [33]; and (2) these same corepressor complexes, which are recruited by antiestrogens, could conceivably contribute to some of tamoxifen’s antitumor effect [34].

Summation of these data indicates that activation or repression of ERα-mediated DNA transcription depends on multiple factors, all of which appear to be contingent on the type of ligand/receptor complex formed, as well as the balance between types of comodulatory proteins recruited. In essence, an intrinsic cellular program mediated through the hormone receptors follows a blueprint for the repetitive...
remodeling of chromatin, regulates the process of gene transcription, and determines specific endocrine effects on target tissue. The importance of the above information is discussed further in sections related to the individual receptors.

4. Sex Hormone Receptors

4.1. ERα. Not by default related to its early discovery, but rather by de facto evidence, both laboratory and clinical data support the conclusion that estrogenic actions in normal breast, as well as in breast cancer, are mediated primarily through ERα. Interestingly, the effect on mammary gland development may be direct or indirect. Compelling evidence of a direct effect comes from the finding that compared to normal mice ERα-knockout (αERKO) mice retain only rudimentary mammary ductal structures despite elevated levels of circulating estradiol [35]. The importance of the receptor being established led to the intriguing question whether oncogene-induced mammary tumors would still develop in αERKO mice. Even though tumor-inducing amplified Human EGFR-Related (HER) 2 could still promote mammary carcinogenesis in this estrogen-insensitive milieu, devoid of ERα, onset of tumor appearance was significantly delayed [36]. These data imply that while the presence of ERα was not absolutely essential for tumor development,
absence of signaling through the hormone receptor transiently repressed tumor promotion or progression. Estrogens may also have an indirect effect on breast tissue by upregulating a number of growth factor genes including epidermal growth factor and insulin-like growth factor-1, both of which may influence, or have a contributory role in, the disease [37,38].

Adding to, or possibly superseding, the importance of tissue ERα expression are the target genes regulated by the receptor. Activated ERα induces transcription of a vast array of genes, which provide valuable insight into the broad range of tumor cell responses that can be mediated through the receptor. Depending on the type, or balance, of modulators recruited to the LBD, the mitogenic effects of estrogens are attributable not only to regulating tumor cell proliferation but also suppressing tumor cell apoptosis. Laboratory evidence indicates that ERα affects transcription of proliferative genes such as proliferating cell nuclear antigen (PCNA) and antiapoptotic genes including survivin and Bcl (B-cell leukemia)-2 [39]. One of the more intriguing estrogen-responsive genes is Wnt11 (a portmanteau of Wg (wingless) in Drosophila and INT 1 (the mammalian homologue of Wg)) [40]. Although there is a strong association between Wnt11 gene expression and hormone-independent growth of prostate cancer cells, its role in breast cancer may not be through Wnt11-mediated tumor cell proliferation but rather inhibition of apoptosis.

It is important to emphasize that the list of ERα target genes mentioned above is by no means exhaustive as other types of genes and their individual role in signal transduction, transcription coactivation, and metabolic enzyme processes are also likely to be relevant but were not included. In addition, the genomic actions of estrogen can be further complicated when ERβ is coexpressed in the same cell.

4.2. ERβ. Regardless whether the terms endocrine responsive, hormone dependent, or ER positive are used to classify a specific subtype of breast cancer, all three descriptors refer singularly to ERα. Notwithstanding ERα’s distinctive status, data continue to accumulate regarding the potential relevance of the second estrogen receptor. Perhaps the most significant biological difference between the two receptors is the growth suppressive effects ERβ imparts on breast cancer cells [41–44]. An ingenious in vitro study conducted using ERβ-transfected MCF-7 (ERα-positive) cells demonstrated the impact on estrogen-mediated cellular responses when both receptors are expressed. In order to establish expression of the approximate percentage of ERβ to ERα (i.e., 30%) observed in most breast cancers, cells were infected with different numbers of ERβ adenovirus [41]. By doing this, the investigators were also able to assess the effect different levels of ERβ expression had on endogenous ERα protein levels. Notably, ERα protein levels decreased significantly in cells where ERβ expression exceeded that ERα, while expression of ERα was unchanged in cells that had the appropriate ratio of receptors.

Interestingly ERβ-induced suppression of tumor cell proliferation has been observed to occur with or without estrogen [42]. Compared to control tumor cells, induced expression of ERβ in MCF-7 cells cultured with estradiol resulted in a dramatic reduction in cell growth. Of note also, a reduction in the basal growth rate was observed in ERβ expressing MCF-7 cells (compared to control tumor cells) in media devoid of ligand. Transcript analysis of the cells provided some plausible mechanisms for the suppressive effects of ERβ. Several proteins involved in cell cycle progression/cell proliferation including CDC25A (cell division cycle 25 homolog A), the E2F1 transcription factor, and the antiapoptotic protein, survivin, were all downregulated by ERβ. In addition, p21WAF1, a negative regulator of the cell cycle, was upregulated by ERβ. Collectively, these findings indicated that the observed effect on MCF-7 cells occurred by modulating both positive and negative regulators of cell growth.

In addition to affecting tumor cell proliferation and survival, lower expression of ERβ in breast cancer (compared to normal breast) suggests the receptor may also have a role in the tumorigenic process. Engineered receptor-null MDA-MB-231 breast cancer cells were transfected with either ERα or ERβ [43]. In the presence of estrogen, both proteins underwent nuclear translocation and were transcriptionally active. However, contrary to their (similar) effect on several estrogen-targeted genes, only ERα could induce the proto-oncogene c-myc. Hence, in contrast to the proliferative effect of ERα, ERβ-mediated transcriptional activation appears to be protective against hormone-dependent breast cancers.

Although coexpression of both ERα and ERβ has been commonly observed, two studies found that approximately half of all ERα− breast tumors expressed ERβ [8, 45]. Of interest also, the absence of ERα, which characterizes two other molecular breast cancer phenotypes (i.e., HER2 and basal-like), somewhat surprisingly expressed ERβ in a substantial number of tumor specimens [8]. Even though the full implications are not known, an inverse relationship between prognostic features such as tumor grade, tumor size, and node involvement and ERβ expression has been reported [8]. In addition, the presence of ERβ has been found to correlate with improvements in a number of disease endpoints including relapse-free survival and overall survival [9, 10]; however, conflicting data have also been reported [46, 47]. Because of the potential value of measuring ERβ, it is important to reconcile these disparate clinical observations. Even though numerous publications suggest that the actions of ERβ are markedly different from ERα, with the former functioning as a tumor suppressor, one major confounding factor that could partially explain the discordant findings may be related to ERβ variants of which (other than wild type) at least four have been identified (Figure 4). Because many studies analyzed ERβ at the transcript level using primer sequences common to all variants, identification of what may be functionally distinct isoforms of the receptor was not ascertained [48, 49]. For example, while estrogen binds to ERβ1 (wild type) [50] and induces transcription of anti-proliferative and pro-apoptotic genes none of the other four variants exhibit high ligand binding affinity. Hence, the apparent protective effect of ERβ1 against ERα-dependent
breast tumors may not extend to hormone-dependent tumors that coexpress ERβ2 or ERδ5 [42, 51]. Transcriptional activity also depends on the each variant’s ability to bind EREs; much uncertainty exists in this regard with ERδ5 and ERδ5 [52, 53]. Other peculiarities that could add to the inconsistent findings include the relatively small numbers of patients studied and immunohistochemical detection of only ERβ1 in tumor samples; the primary reason for the latter is often attributed to lack of variant-specific antibodies [54]. Finally, what may be extremely important is the dominant negative activity of ERβ1, ERβ2, and ERδ5 against ERα which is discussed in the following section.

4.3. ERα/ERβ1 Heterodimer. Even though the ERs are encoded by two different genes [55], the receptors share a number of similarities. For example, the homology of the DNA (C) binding domain is nearly identical, their transactivation properties are similar, and both receptors bind to consensus ERE. Nonetheless, and despite some overlapping gene regulatory activities substantial structural and functional differences between the two transcription factors have been reported [16]. Of the five major domains, the greatest between-receptor disparities occur in the N-terminus (A/B domain) and ligand-binding (E) domains. The relevance of these findings relates to transcriptional AF-1 and AF-2, which are localized to the A/B and E domains, respectively. Furthermore, AF-1 and AF-2 determine both cell- and promoter-specific activities as well as interactions with comodulatory proteins [16]. In addition each receptor’s dependence on AF-2 is remarkably different. Whereas AF-1 of ERα can function independently of ligand and AF-2, that of ERβ1 appears totally dependent on ligand-activated AF-2. Moreover, when AF-1 and AF-2 are both activated, the functional activity of homodimeric ERα predominates over the ERβ1 homodimer [16].

However, another aspect of the dimer concept completely debunks the notion of ERβ’s subservient role in relation to ERα-mediated transcriptional activity. Whereas genomic actions of estrogens resulting in tumor cell proliferation and survival have been shown to occur via homodimeric ERα, there is the distinct possibility that some of the ERβ variants could antagonize these effects through heterodimerization.
tamoxifen has pure antagonist effects on ER. The formation of ER is also increased transcription of genes not affected by either homodimer [61, 62]. However, one of the more confounding issues related to ER involves the formation of ERα/ERβ splice variant heterodimers. Because tamoxifen has pure antagonist effects on ER β, the finding that a greater proportion of ERβ-negative tumors responded to the antiestrogen implies that expression of ERβ is associated with poor response and hence clinical outcomes. This notion is certainly consistent with the concept that antitumor effects achieved through ER blockade could be partially counteracted by inhibiting the growth inhibitory effects mediated by ERβ [49]. On the other hand, some studies have found that expression of ERβ was associated with significant improvement in relapse-free survival and overall survival [63, 64]. Though the findings are inconsistent, the clinical endpoints may be independent of tamoxifen's effect on ERβ (as well as formation of the α/β1 heterodimer) because of altered ligand binding due to changes in the truncated C-terminus of the protein and loss of the AF-2 domain [65].

Of interest also is the expression of the progesterone receptor (PR), which is known to be regulated by ERα [66]. Because the presence of ERβ1 has been shown to repress transactivation of the PR gene [67], the heterodimer, in a manner similar to its antiproliferative effects, could also suppress this ERα-target gene. Moreover, this finding could explain the clinical phenomenon of ER+/PR− breast cancers. These findings suggest not only that genomic action (and hence, biological effect) of estrogens differs depending on receptor dimeric state but also the possibility of a reciprocal influence each receptor has on the other (Table 1).

4.4. AR. The finding that expression of AR is ubiquitous in both males and females suggests that androgens are likely to have an impact in various tissues including the breast. Even though the actions of androgens are believed to oppose that of estrogens, the inhibitory effect of androgens on breast tissue depends largely on the relative tissue concentrations of both types of hormones as well as their receptor-mediated actions. This conclusion is consistent with two observations: (1) breasts do not undergo normal development in girls diagnosed with androgen-secreting adrenal tumors despite adequate circulating estrogens [68] and (2) development of gynecomastia in men treated with AR blockers for prostate cancer [69]. Clinically, a possible link has been established between AR expression and outcomes in certain subsets of breast cancer [70, 71]. Moreover, therapeutic application of androgens predated the selective estrogen receptor modulators in postmenopausal women with breast cancer [72, 73].

Relative to ERα, the role of androgens in breast cancer growth and disease progression is less well understood. This level of uncertainty and, perhaps, appreciation persists in spite of the apparent correlation between tumor cell expression of AR in the majority of human breast cancers and various features of the disease mentioned earlier in this paper. The importance attached to this discordance necessitates a brief discussion of several salient issues. First, epidemiological studies have, on occasion, reached different conclusions with respect to androgens and breast cancer with the hormones either enhancing the protection against or increasing the risk for the disease [74]. One of the major reasons for this discrepancy relates to the validity of the correlation between disease risk and serum androgen concentrations [75]. Reliance on blood levels alone, however, obscures the potential importance of extragonadal synthesis of androgens (and estrogens). Identification of all the requisite enzymes including the 5α-reductases and both 3β- and 17β-hydroxysteroid dehydrogenases in peripheral tissue supports the relevance of a biological process known as intracrinology (Figure 5). That locally produced androgens can exert their actions in an intracrine manner may have added importance especially in postmenopausal women, who not only have a higher risk of breast cancer but who also rely on peripheral synthesis of nearly all sex hormones from adrenal-derived dehydroepiandrosterone (DHEA) [76]. Moreover, the best indicator of the total androgen reservoir as well as androgenic activity has been shown to be the conjugated metabolites of dihydrotestosterone (DHT), not the active hormone [76].

Second, results of in vitro studies are discordant even in AR+ breast cancer cell lines [77]. When exposed to DHT, a proliferative response occurred in both MDA-MB-453 cells (AR+/ER−) and MCF-7 (AR+/ER+) cells; however, an anti-proliferative effect was observed in two other AR+/ER− cell lines, T47D and ZR-75.1. One of the more intriguing explanations for the differential effect on proliferation in ER− and ER+ tumor cell lines may involve an interaction between AR and HER2 as both receptors are coexpressed in approximately 50% of ER− breast cancers [78]. In breast cancers classified as molecular apocrine subtype, androgen-induced proliferation involves activation of the extracellular signal-regulated-kinase-(ERK-) signal transduction pathway. However, the AR link to ERK has been shown to be dependent on transcriptional upregulation of the HER2 gene. Hence, a functional feedback loop has been postulated in this type of breast cancer which includes AR, HER2, ERK, and an ERK transcription factor that binds to a promoter region on the AR gene [79]. What is also notable about this study is that a number of possible confounding causes for the divergent cellular responses such as cell density at time of drug exposure and serum used in the culture medium were eliminated by the meticulous methodology used by the investigators. Another plausible explanation for the discrepant results is the involvement of AR-independent pathways. Because androgens such as DHT can be metabolized (not aromatized) in vitro, one metabolite has been shown to bind ERα resulting in the proliferation of the MCF-7 cells [80]. It should also be mentioned that even though AR levels varied markedly between the different cell lines, receptor numbers alone cannot account for the divergent effects on proliferation. This conclusion is supported by the contrasting results observed in the two cell lines with the highest level of AR, MDA-MB-453, and ZR-75.1. In addition, despite a 6-fold lower AR
expression, MCF-7 cells had a similar proliferative response as MDA-MB-453 cells.

Even more perplexing is one other finding related to androgen action in MCF-7 breast cancer cells. While proliferation of MCF-7 breast cancer cells has been shown to occur even in the absence of estrogens, the proliferative effect may not be mediated through the androgen receptor pathway. In the presence of supra-physiological concentrations of DHT, nuclear translocation of both AR and ER occurred. That the stimulatory effect of DHT could have been mediated via ER was supported by increased expression of PR and the inability of antiandrogens to inhibit tumor cell growth [81]. This in vitro approach demonstrated that at physiological levels of DHT the androgen does not compete with estradiol for ERα binding. In addition, an intriguing in vivo correlate exists, one where breast tumor cells with negligible expression of ERα are exposed to high levels of androgens. In this clinically possible setting, it is rational to suggest that the rather promiscuous affinity of androgen, or an androgen metabolite [82], for the estrogen receptor provides a plausible explanation for tumors being characterized as ER−/PR+.

Third, clinical data indicate that expression of AR occurs more frequently than ER in breast tumor tissue. Interestingly, 10%–35% of triple negative and up to 60% of ER−/PR−/HER2+ breast cancers have been reported to express AR [71, 83–85]. However, unlike ERα, AR expression alone may not be predictive of response as anticancer benefits have been demonstrated with both androgens and antiandrogens. These confounding findings strongly suggest that other factors, including signaling through the epidermal growth factor receptor (EGFR) and HER2 pathways or activation of a key intermediary downstream kinase such as mitogen-activated protein kinase (MAPK), may contribute to the complex repertoire of androgen-mediated effects [86, 87]. The contribution of other signaling pathways has been nicely demonstrated in an ERα−/PR− breast cancer cell line engineered to express AR. While upregulation of the AR-target gene p21WAF1 promoted tumor cell proliferation through the MAPK pathway, hyperactivation of MAPK by concurrent AR and EGFR-signaling pathways caused tumor growth suppression [88, 89].

Fourth, despite the frequency of AR expression in primary breast cancers, the function and role of the receptor may not be the same as in prostate cancer. This conclusion is supported by several findings regarding androgen signaling in both endocrine-related cancers. For instance, AR gene amplification is frequently observed in prostate cancer but not in breast cancer, despite receptor overexpression [90]. Whereas high AR expression has been correlated with poorer outcomes in prostate cancer, some investigators have found a direct correlation between AR expression and survival in patients with breast cancer [13, 91, 92]. Nonetheless, high
AR expression may provide an advantage for both cancers especially since serum androgen and adrenal-derived DHEA levels, although markedly reduced by androgen- ablative therapy or aging, can be partially blunted by the process of intracrinology.

5. Hormone Receptor Milieu in Breast Cancer

Very compelling evidence support the belief that, in contrast to estrogen-induced proliferation of ERα+ tumor cells, tumor suppressive effects are mediated through ERβ regardless of the second receptor that is expressed alone or in the presence of ERα [93]. This distinction may be clinically relevant to what has been traditionally labeled hormone receptor positive, and possibly, even hormone receptor negative breast cancer. One therapeutic implication relates to endoxifen, often regarded as the most potent metabolite of tamoxifen cancer. One therapeutic implication relates to endoxifen, to what has been traditionally labeled hormone receptor positive or negative. This finding suggested that the presence of ERβ1 appeared to intensify the antagonistic effects of endoxifen. Though speculative, it is conceivable that the expression status of ERβ1, which was not assessed in all of the CYP2D6 studies, could partially explain the conflicting predictive role of CYP2D6 pharmacogenomics and breast cancer outcomes [95]. Lastly, 17 biological pathways were found to be unique to either the control or the MCF-7 ERβ1 cell lines. Two ERα-mediated pathways, one involving the regulation of G1/S cell cycle progression and the other cell migration, could be affected by endoxifen only if the cells coexpressed ERβ1. Even though the gene expression pattern observed in the transfected cells could be linked to either ER homodimer, the degradation of ERα suggests that changes in the gene profile, as well as the enhanced antiestrogen effect of endoxifen, may result from the inhibition of ERα/ERβ1 heterodimer.

Interesting also is the apparent paradox related to the role of estrogens in tumor cell survival and tumor cell death with the latter being mediated by mechanisms other than hormone deprivation. As certain as we were about tumor cell survival, both clinical and laboratory data unexpectedly demonstrated that, under certain circumstances, introduction of low doses of estrogens appears to have a protective effect on breast cancer [96, 97]. This “anti-tumor” effect was observed among surgically castrated postmenopausal women randomized to hormone replacement therapy as well as in a tamoxifen-resistant MCF-7 cell line. Notably, long-term estrogen deprivation appears to modulate apoptotic pathways of both normal and cancer cells either by inducing expression of proteins involved in the extrinsic cell-death pathway such as FasR/Fasl or affecting regulatory components of the mitochondrial (i.e., intrinsic) apoptotic pathway including induction of the proapoptotic proteins Bax, Bak, and Bim [98]. While this may be the most reasonable explanation, it is also possible that actions mediated by ERβ1 or AR could have modulated cell survival. What may be more intriguing about AR as a breast cancer target relates to a novel finding in ER−/AR+/HER2+ tumor samples [84]. Particularly alluring was the gene expression profile, one aspect of which indicated that AR-mediated signaling upregulated WNT7B transcription and activated β-catenin. Through their collaborative effort, AR and β-catenin were directly linked to androgen-induced HER3 expression and, indirectly, to the pernicious tumor characteristics imparted by the HER2/HER3 heterodimer [99]. As such, suppression of HER2 signaling as well as formation of the heterodimer could be achieved by AR inhibitors.

Equally engaging is the concept that aberrations of the encoding genes may not only influence hormonal actions, but also breast cancer risk. That hormone insensitivity observed with other nuclear receptors has been positively linked to alterations in their respective genes, deletions, rearrangements, and point mutations in the ERα gene could, vis-a-vis, also be associated with susceptibility to developing the disease. Indeed, even before data from the Human Genome and the HapMap projects were published, genotyping technology was being utilized to determine whether sequence variations or single-nucleotide polymorphisms (SNPs) in the ER genes were associated with disease risk. Two of the better characterized variants in the ERα gene are PvuII, a two-allele (1 and 0) restriction fragment-length polymorphism (RFLP) and XbaI. Even so, conflicting published data abound. For example, results of several studies indicated a significant, but not complete, correlation between the PvuII genotype and ERα-positive breast cancers [100, 101]. In contrast, another study found that the prevalence of ERα-positive tumors was highest among women homozygous or heterozygous for the 0 (i.e., Pvu00 and Pvu01) allele and lowest in those harboring the ERα gene PvuII alleles [102]. Despite the contradictory data, the relatively weak overall correlation between RFLP genotype and ERα expression found in both studies suggests that this aberration in genomic sequence may not be linked to disease risk or receptor phenotype. The latter conclusion is supported by numerous other studies which found no frequency difference of the PvuII polymorphism between breast cancer cases and controls [102–104]. Similar contrary findings have been reported for the XbaI polymorphism [101, 103, 104]. Polymorphisms of the ERβ1 gene have also been detected, and though there may be an association between the identified SNPs and disease risk, the data are way too preliminary to be of substantive value [105–107].

6. Conclusion

Embedded in the widely accepted dogma that estrogens are carcinogenic in breast tissue is the pivotal role of the estrogen
receptor, specifically ERα. Nonetheless, accumulating evidence suggests that ERβ1 and possibly AR also appear to have influential actions in the mammary gland. If the clinical relevance of especially ERβ1 and AR can be firmly established, several new intrinsic subtypes of endocrine-sensitive breast cancers may emerge and subsequently undergo gene expression profiling. Unique in terms of their hormone dependency, each subtype may require a different hormonal approach in order to improve disease outcome. And while reference to ER+ (i.e., ERα+/PR−) breast cancer will still be appropriate, designation of specific double (i.e., ERα/ERβ-variant, ERα/AR, and ERβ-variant/AR) or triple (i.e., ERα, ERβ-variant, and AR) hormone receptor-positive tumors may have greater clinical significance. Moreover, truly hormone receptor-negative breast cancers are apt to be less frequently diagnosed, incrementally more likely not to benefit from any type of hormonal intervention, and, perhaps, even be of better prognostic value.

Although ERα is one of the oldest tumor targets, clinical evidence validates the conclusion that estrogen-deprivation strategies is the most effective way to treat hormone-dependent breast cancer. And despite the translational achievement between laboratory and clinic with approval of agents targeting ERα, the expected concordance between construct inhibition and tumor eradication has, in some respects, been overestimated. The apparent incongruence suggests that mere identification of the target(s), regardless of its (their) purported functional importance, exaggerates our knowledge of tumor cell signaling pathways which ultimately controls cancer cell growth and survival. Until all hormone receptor components are fully understood, the optimal clinical impact of antihormonal therapies will not be fully realized.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**References**

[1] S. Boyd, "On oophorectomy in cancer of the breast," *British Medical Journal*, vol. 2, pp. 1161–1167, 1900.

[2] V. E. Jensen, I. H. Jacobson, A. A. Walf, and A. C. Frye, "Basic guides to the mechanism of estrogen action," *Recent Progress in Hormone Research*, vol. 18, pp. 318–414, 1962.

[3] M. P. Cole, C. T. Jones, and I. D. Todd, "A new anti-oestrogenic agent in late breast cancer, an early clinical appraisal of ICI46474," *British Journal of Cancer*, vol. 25, no. 2, pp. 270–275, 1971.

[4] B. Fisher, C. Redmond, E. R. Fisher, and R. Caplan, "Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjunctive breast and bowel project protocol B-06," *Journal of Clinical Oncology*, vol. 6, no. 7, pp. 1076–1087, 1988.

[5] T. Sotlie, C. M. Perou, R. Tibshirani et al., "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 19, pp. 10869–10874, 2001.

[6] S. Paik, G. Tang, S. Shak et al., "Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer," *Journal of Clinical Oncology*, vol. 24, no. 23, pp. 3726–3734, 2006.

[7] G. G. J. M. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.-Å. Gustafsson, "Cloning of a novel estrogen receptor expressed in rat prostate and ovary," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 12, pp. 5925–5930, 1996.

[8] J. D. Marotti, L. C. Collins, R. Hu, and R. M. Tanimmii, "Estrogen receptor-β expression in invasive breast cancer in relation to molecular phenotype: results from the nurses’ health study," *Modern Pathology*, vol. 23, no. 2, pp. 197–204, 2010.

[9] W. R. Miller, T. J. Anderson, J. M. Dixon, and P. T. K. Saunders, "Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment," *British Journal of Cancer*, vol. 94, no. 9, pp. 1333–1338, 2006.

[10] N. Honma, R. Horii, T. Iwase et al., "Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy," *Journal of Clinical Oncology*, vol. 26, no. 22, pp. 3727–3734, 2008.

[11] E. Engelsman, C. B. Korsten, J. P. Persijn, and F. J. Cleton, "Proceedings: oestrogen and androgen receptors in human breast cancer," *British Journal of Cancer*, vol. 30, no. 2, article 177, 1974.

[12] S. Park, J. Koo, H. S. Park et al., "Expression of androgen receptors in primary breast cancer," *Annals of Oncology*, vol. 21, no. 3, pp. 488–492, 2010.

[13] S. N. Agoff, P. E. Swanson, H. Linden, S. E. Hawes, and T. J. Lawton, "Androgen receptor expression in estrogen receptor-negative breast cancer: immunohistochemical, clinical, and prognostic associations," *American Journal of Clinical Pathology*, vol. 120, no. 5, pp. 725–731, 2003.

[14] F. Moinfar, M. Okcu, O. Tsyabrovska et al., "Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies," *Cancer*, vol. 98, no. 4, pp. 703–711, 2003.

[15] D. J. Mangelsdorf, C. Thummler, M. Beato et al., "The nuclear receptor superfamily: the second decade," *Cell*, vol. 83, no. 6, pp. 835–839, 1998.

[16] S. M. Cowley and M. G. Parker, "A comparison of transcriptional activation by ERα and ERβ," *Journal of Steroid Biochemistry and Molecular Biology*, vol. 69, no. 1–6, pp. 165–175, 1999.

[17] M. Truss and M. Beato, "Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors," *Endocrine Reviews*, vol. 14, no. 4, pp. 459–479, 1993.

[18] K. Dahlman-Wright, A. Wright, J. Gustafsson, and J. Carlstedt-Duke, "Interaction of the glucocorticoid receptor DNA-binding domain with DNA as a dimer is mediated by a short segment of five amino acids," *Journal of Biological Chemistry*, vol. 266, no. 5, pp. 3107–3112, 1991.

[19] C. K. Glass, "Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers," *Endocrine Reviews*, vol. 15, no. 3, pp. 391–407, 1994.

[20] J. W. R. Schwabe, L. Chapman, J. T. Finch, and D. Rhodes, "The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements," *Cell*, vol. 75, no. 3, pp. 567–578, 1993.

[21] E. Schoenmakers, G. Verrijdt, B. Peeters, G. Verhoeven, W. Rombauts, and F. Claessens, "Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can
determine hormone-specific responses,” *Journal of Biological Chemistry*, vol. 275, no. 16, pp. 12290–12297, 2000.

[22] E. Langley, Z.-X. Zhou, and E. M. Wilson, “Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer,” *Journal of Biological Chemistry*, vol. 270, no. 50, pp. 29983–29990, 1995.

[23] J. A. Kemppainen, E. Langley, C.-I. Wong, K. Bobseine, W. R. Kelce, and E. M. Wilson, “Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone,” *Molecular Endocrinology*, vol. 13, no. 3, pp. 440–454, 1999.

[24] Z.-X. Zhou, M. V. Lane, J. A. Kemppainen, F. S. French, and E. M. Wilson, “Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability,” *Molecular Endocrinology*, vol. 9, no. 2, pp. 208–218, 1995.

[25] J. Li, J. Fu, C. Toumazou, H.-G. Yoon, and J. Wong, “A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin,” *Molecular Endocrinology*, vol. 20, no. 4, pp. 776–785, 2006.

[26] P. Doesburg, C. W. Kuil, C. A. Berrevoets et al., “Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor,” *Biochemistry*, vol. 36, no. 5, pp. 1052–1064, 1997.

[27] A. M. Brzozowski, A. C. W. Pike, Z. Dauter et al., “Molecular basis of agonism and antagonism in the oestrogen receptor,” *Nature*, vol. 389, no. 6652, pp. 753–758, 1997.

[28] J. S. Sack, K. F. Kish, C. Wang et al., “Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 9, pp. 4904–4909, 2001.

[29] D. M. Heery, E. Kalkhoven, S. Hoare, and M. G. Parker, “A signature motif in transcriptional co-activators mediates binding to nuclear receptors,” *Nature*, vol. 387, no. 6634, pp. 733–736, 1997.

[30] G. Jenster, H. A. G. M. Van der Korput, J. Trapman, and A. O. Brinkmann, “Identification of two transcription activation units in the N-terminal domain of the human androgen receptor,” *Journal of Biological Chemistry*, vol. 270, no. 13, pp. 7341–7346, 1995.

[31] C. L. Smith and B. W. O’Malley, “Coregulator function: a key to understanding tissue specificity of selective receptor modulators,” *Endocrine Reviews*, vol. 25, no. 1, pp. 45–71, 2004.

[32] J. Lopez-Garcia, M. Periyasamy, S. R. Thomas et al., “ZNF366 is an estrogen receptor corepressor that acts through CBP and histone deacetylases,” *Nucleic Acids Research*, vol. 34, pp. 6126–6136, 2006.

[33] T. Ishizuka and M. A. Lazar, “The N-COR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor,” *Molecular and Cellular Biology*, vol. 23, no. 15, pp. 5122–5131, 2003.

[34] P. Webb, P. Nguyen, and P. J. Kushner, “Differential SERM effects on corepressor binding dictate ERα activity in vivo,” *Journal of Biological Chemistry*, vol. 278, no. 9, pp. 6912–6920, 2003.

[35] W. P. Bocchinfuso and K. S. Korach, “Mammary gland development and tumorigenesis in estrogen receptor knockout mice,” *Journal of Mammary Gland Biology and Neoplasia*, vol. 2, no. 4, pp. 323–334, 1997.

[36] S. C. Hewitt, W. P. Bocchinfuso, J. Zhai et al., “Lack of ductal development in the absence of functional estrogen receptor α delays mammary tumor formation induced by transgenic expression of ErbB2/neu,” *Cancer Research*, vol. 62, no. 10, pp. 2798–2805, 2002.

[37] G. J. Todaro, T. M. Rose, C. E. Spooner, M. Shoyab, and G. D. Plowman, “Cellular and viral ligands that interact with the egf receptor,” *Seminars in Cancer Biology*, vol. 1, no. 4, pp. 257–263, 1990.

[38] D. L. Kleinberg, “Early mammary development: growth hormone and IGF-1,” *Journal of Mammary Gland Biology and Neoplasia*, vol. 2, no. 1, pp. 49–57, 1997.

[39] Z. Lin, S. Reierstad, C.-C. Huang, and S. E. Bulun, “Novel estrogen receptor-α binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer,” *Cancer Research*, vol. 67, no. 10, pp. 5017–5024, 2007.

[40] A. Klaus and W. Birchmeier, “Wnt signalling and its impact on development and cancer,” *Nature Reviews Cancer*, vol. 8, no. 5, pp. 387–398, 2008.

[41] P. Roger, M. E. Sahla, S. Mäkelä, J. Å. Gustafsson, P. Baldet, and H. Rochefort, “Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors,” *Cancer Research*, vol. 61, no. 6, pp. 2537–2541, 2001.

[42] E. C. Chang, J. Frasor, B. Komin, and B. S. Katzenellenbogen, “Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells,” *Endocrinology*, vol. 147, no. 10, pp. 4831–4842, 2006.

[43] G. Lazennec, D. Bresson, A. Lucas, C. Chauveau, and F. Vignon, “ERβ inhibits proliferation and invasion of breast cancer cells,” *Endocrinology*, vol. 142, no. 9, pp. 4120–4130, 2001.

[44] S. Paruthiyil, H. Parmar, V. Kerekatte, G. R. Cunha, G. L. Firestone, and D. C. Leitmann, “Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest,” *Cancer Research*, vol. 64, no. 1, pp. 423–428, 2004.

[45] G. P. Skiriris, E. Leygue, L. Curtis-Snell, P. H. Watson, and L. C. Murphy, “Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours,” *British Journal of Cancer*, vol. 95, no. 5, pp. 616–626, 2006.

[46] P. A. O’Neill, M. P. A. Davies, A. M. Shaaban et al., “Wild-type oestrogen receptor beta (ERβ1) mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers,” *British Journal of Cancer*, vol. 91, no. 9, pp. 1694–1702, 2004.

[47] E. V. Jensen, G. Cheng, C. Palmieri et al., “Estrogen receptors and proliferation markers in primary and recurrent breast cancer,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 26, pp. 15197–15202, 2001.

[48] P. D. Cremoux, C. Tran-Perennou, C. Elie et al., “Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction: correlation with protein assays,” *Biochemical Pharmacology*, vol. 64, no. 3, pp. 507–515, 2002.

[49] I. Bieche, B. Parfait, I. Laurendeau, I. Girault, M. Vidaud, and R. Lidereau, “Quantification of estrogen receptor α and β expression in sporadic breast cancer,” *Oncogene*, vol. 20, no. 56, pp. 8109–8115, 2001.

[50] S. Saji, H. Sakaguchi, S. Andersson, M. Warner, and J.-Å. Gustafsson, “Quantitative analysis of estrogen receptor proteins in rat mammary gland,” *Endocrinology*, vol. 142, no. 7, pp. 3177–3186, 2001.

[51] S. Saji, Y. Omoto, C. Shimizu et al., “Expression of estrogen receptor (ER) β cx protein in ERα-positive breast cancer: specific correlation with progesterone receptor,” *Cancer Research*, vol. 62, no. 17, pp. 4849–4853, 2002.
Palmieri, E. W. Lam, J. Mansie et al., "The expression of estrogen receptor β messenger RNA variant in breast cancer," Cancer Research, vol. 58, no. 2, pp. 210–214, 1998.

C. Palmieri, G. J. Cheng, S. Saji et al., "Estrogen receptor beta in breast cancer," Endocrine-Related Cancer, vol. 9, no. 1, pp. 1–13, 2002.

K. Iwao, Y. Miyoshi, C. Egawa, N. Ikeda, F. Tsukamoto, and S. Noguchi, "Quantitative analysis of estrogen receptor-alpha and beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction," Cancer, vol. 89, pp. 1732–1738, 2000.

E. Nenmark, M. Pelto-Huikko, K. Grandien et al., "Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern," The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 12, pp. 4258–4265, 1997.

L. A. Helguero, M. H. Faulds, J.-Å. Gustafsson, and L.-A. Haldosen, "Estrogen receptors alfa (ERα) and beta (ERβ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HCII," Oncogene, vol. 24, no. 44, pp. 6605–6616, 2005.

K. Pettersson, F. Delauaney, and J.-A. Gustafsson, "Estrogen receptor β acts as a dominant regulator of estrogen signaling," Oncogene, vol. 19, no. 43, pp. 4970–4978, 2000.

S. Saji, M. Hirose, and M. Töi, "Clinical significance of estrogen receptor β in breast cancer," Cancer Chemotherapy and Pharmacology, vol. 56, no. 7, supplement, pp. s21–s26, 2005.

S. M. Cowley, S. Hoare, S. Mosselman, and M. G. Parker, "Estrogen receptors α and β form heterodimers on DNA," Journal of Biological Chemistry, vol. 272, no. 32, pp. 19858–19862, 1997.

K. Pettersson, K. Grandien, G. G. J. M. Kuiper, and J.-Å. Gustafsson, "Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α," Molecular Endocrinology, vol. 11, no. 10, pp. 1486–1496, 1997.

L. C. Murphy, B. Peng, A. Lewis et al., "Inducible upregulation of oestrogen receptor-β1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells," Journal of Molecular Endocrinology, vol. 34, no. 2, pp. 535–566, 2005.

Z. Papoutsi, C. Zhao, M. Putnik, J.-Å. Gustafsson, and K. Dahman-Wright, "Binding of estrogen receptor α/β heterodimers to chromatin in MCF-7 cells," Journal of Molecular Endocrinology, vol. 43, no. 2, pp. 65–72, 2009.

M. P. A. Davies, P. A. O'Neill, H. Innes et al., "Correlation of mRNA for oestrogen receptor beta splice variants ERβ1, ERβ2/ERβfcx and ERβ5 with outcome in endocrine-treated breast cancer," Journal of Molecular Endocrinology, vol. 33, no. 3, pp. 773–782, 2004.

C. Palmieri, E. W. Lam, J. Mansi et al., "The expression of ERbeta2c in human breast cancer and the relationship to endocrine therapy and survival," Clinical Cancer Research 2004, vol. 10, pp. 2421–2428.

J. T. Moore, D. D. McKee, K. Slentz-Kesler et al., "Cloning and characterization of human estrogen receptor β isoforms," Biochemical and Biophysical Research Communications, vol. 247, no. 1, pp. 75–78, 1998.

S. C. Hewitt and K. S. Korach, "Progestosterone action and responses in the αERKO mouse," Steroids, vol. 65, no. 10-11, pp. 551–557, 2000.

J. Matthews, B. Wihlén, M. Tujague, J. Wan, A. Ström, and J.-Å. Gustafsson, "Estrogen receptor (ER) β modulates ERα-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters," Molecular Endocrinology, vol. 20, no. 3, pp. 534–543, 2006.

G. Forsbach, A. Gutiérn-Cantu, J. Vázquez-Lara, M. Mota-Morales, and M. L. Díaz-Mendoza, "Virilizing adrenal adenoma and primary amenorrhea in a girl with adrenal hyperplasia," Archives of Gynecology and Obstetrics, vol. 263, no. 3, pp. 134–136, 2000.

A. Dobs and M. J. M. Darkes, "Incidence and management of gynecomastia in men treated for prostate cancer," Journal of Urology, vol. 174, no. 5, pp. 1737–1742, 2005.

G. Buchanan, S. N. Birrell, A. A. Peters et al., "Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate," Cancer Research, vol. 65, no. 18, pp. 8487–8496, 2005.

A. Gucalp and T. A. Traina, "Triple-negative breast cancer: role of the androgen receptor," Cancer Journal, vol. 16, no. 1, pp. 62–65, 2010.

E. F. Adair and B. J. Herrmann, "The use of testosterone propionate in the treatment of advanced carcinoma of the breast," Annals of Surgery, vol. 123, pp. 1023–1035, 1946.

B. J. Kennedy, "Fluoxymesterone therapy in advanced breast cancer," The New England Journal of Medicine, vol. 259, no. 14, pp. 673–675, 1958.

A. H. Eliassen, S. A. Missmer, S. T. Urow et al., "Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women," Journal of the National Cancer Institute, vol. 98, no. 19, pp. 1406–1415, 2006.

T. J. Key, P. Appleby, L. Barnes, and G. Reeves, "Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies," Journal of the National Cancer Institute, vol. 94, no. 8, pp. 606–616, 2002.

F. Labrie, A. Bélanger, L. Cusan, and B. Candás, "Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology," Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 8, pp. 2403–2409, 1997.

S. N. Birrell, J. M. Bentel, T. E. Hickey et al., "Androgens induce divergent proliferative responses in human breast cancer cell lines," Journal of Steroid Biochemistry and Molecular Biology, vol. 52, no. 5, pp. 459–467, 1995.

A. Naderi and L. Hughes-Davies, "A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer," Neoplasia, vol. 10, no. 6, pp. 542–548, 2008.

K. M. Chia, J. Liu, G. D. Francis, and A. Naderi, "A feedback loop between androgen receptor and erk signaling in estrogen receptor-negative breast cancer," Neoplasia, vol. 13, no. 2, pp. 154–166, 2011.
[83] M. Ni, Y. Chen, E. Lim et al., “Targeting androgen receptor in estrogen receptor-negative breast cancer,” *Cell Cancer*, vol. 20, no. 1, pp. 119–131, 2011.

[84] A. L. Niemeier, D. J. Dabbs, S. Beriwal, J. M. Striebel, and R. Bhargava, “Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation,” *Modern Pathology*, vol. 23, no. 2, pp. 205–212, 2010.

[85] S. Park, J. Koo, H. S. Park et al., “Expression of androgen receptors in primary breast cancer,” *Annals of Oncology*, vol. 21, no. 3, Article ID mdp510, pp. 488–492, 2010.

[86] J.-C. Pignon, B. Koopmansch, G. Nolens, L. Delacroix, D. Waltregny, and R. Winkler, “Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines,” *Cancer Research*, vol. 69, no. 7, pp. 2941–2949, 2009.

[87] I. K. Mellinhoff, I. Vivanco, A. Kwon, C. Tran, J. Wongvipat, and C. L. Sawyers, “HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability,” *Cancer Cell*, vol. 6, no. 5, pp. 517–527, 2004.

[88] S. Lu, G. Jenster, and D. E. Epner, “Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex,” *Molecular Endocrinology*, vol. 14, no. 5, pp. 753–760, 2000.

[89] J. P. Garay, B. Karakas, A. M. Abukhdeir et al., “The growth activation of human T47D breast cancer cells,” *Toxicological Sciences*, vol. 13, no. 2, article R27, 2012.

[90] T. Visakorpi, E. Hyttinen, P. Koivisto et al., “In vivo amplification of the androgen receptor gene and progression of human prostate cancer,” *Nature Genetics*, vol. 9, no. 4, pp. 401–406, 1995.

[91] Y. Ogawa, E. Hai, K. Matsumoto et al., “Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers,” *International Journal of Clinical Oncology*, vol. 13, no. 5, pp. 431–435, 2008.

[92] E. A. Rakha, M. E. El-Sayed, A. R. Green, A. H. S. Lee, J. F. Robertson, and J. O. Ellis, “Prognostic markers in triple-negative breast cancer,” *Cancer*, vol. 109, no. 1, pp. 25–32, 2007.

[93] A. M. S. Covaleda, H. Van den Berg, J. Vervoort et al., “Influence of cellular ERα/ERβ ratio on the ERα-agonist induced proliferation of human T47D breast cancer cells,” *Toxicological Sciences*, vol. 105, no. 2, pp. 303–311, 2008.

[94] X. Wu, M. Subramaniam, S. B. Grygo et al., “Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen,” *Breast Cancer Research*, vol. 13, no. 2, article R27, 2011.

[95] M. M. Regan, B. Leyland-Jones, M. Bouzyk et al., “CYP2D6 Genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial,” *Journal of the National Cancer Institute*, vol. 104, no. 6, pp. 441–451, 2012.

[96] A. Z. LaCroix, R. T. Chlebowski, J. E. Manson et al., “Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial,” *Journal of the American Medical Association*, vol. 305, no. 13, pp. 1305–1314, 2011.

[97] J. S. Lewis, K. Meeke, C. Osipo et al., “Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation,” *Journal of the National Cancer Institute*, vol. 97, no. 23, pp. 1746–1759, 2005.

[98] J. Baselga and S. M. Swain, “Novel anticancer targets: revisiting ERBB2 and discovering ERBB3,” *Nature Reviews Cancer*, vol. 9, no. 7, pp. 463–475, 2009.

[99] S. T. Lee-Hoeflich, L. Crocker, E. Yao et al., “A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy,” *Cancer Research*, vol. 68, no. 14, pp. 5878–5887, 2008.

[100] S. M. Hill, S. A. W. Fuqua, G. C. Chamness, G. L. Greene, and W. L. McGuire, “Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism,” *Cancer Research*, vol. 49, no. 1, pp. 145–148, 1989.

[101] Q. Cai, X.-O. Shu, F. Jin et al., “Genetic polymorphisms in the estrogen receptor α gene and risk of breast cancer: results from the Shanghai breast cancer study,” *Cancer Epidemiology Biomarkers and Prevention*, vol. 12, no. 9, pp. 853–859, 2003.

[102] L. Yaich, W. D. Dupont, D. R. Cavener, and F. F. Parl, “Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood,” *Cancer Research*, vol. 52, no. 1, pp. 77–83, 1992.

[103] T. I. Andersen, K. R. Heimdal, M. Skrede, K. Tveit, K. Berg, and A.-L. Borresen, “Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility,” *Human Genetics*, vol. 94, no. 6, pp. 665–670, 1994.

[104] A. Shin, D. Kang, H. Nishio et al., “Estrogen receptor alpha gene polymorphisms and breast cancer risk,” *Breast Cancer Research and Treatment*, vol. 80, no. 1, pp. 127–131, 2003.

[105] A. Försti, C. Zhao, E. Isaedssson, K. Dahlman-Wright, J.-Å. Gustafsson, and K. Hemminki, “Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association,” *Breast Cancer Research and Treatment*, vol. 79, no. 3, pp. 409–413, 2003.

[106] S. L. Zheng, W. Zheng, B.-L. Chang et al., “Joint effect of estrogen receptor β sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women,” *Cancer Research*, vol. 63, no. 22, pp. 7624–7629, 2003.

[107] P. Maguire, S. Margolin, J. Skoglund et al., “Estrogen receptor beta (ERβ2) polymorphisms in familial and sporadic breast cancer,” *Breast Cancer Research and Treatment*, vol. 94, no. 2, pp. 145–152, 2005.